Clinical impact of a humanized CCR4 antibody (mogamulizumab) in 14 patients with aggressive adult T-cell leukemia-lymphoma treated at a single institution during a three-year period (2012-2014)

Internal Medicine

Volumn 55, Issue 11, 2016, Pages 1439-1445

  Kawano, Noriaki ^a   Kuriyama, Takuro ^a   Sonoda, Koh Hei ^b   Yoshida, Shuro ^a   Yamashita, Kiyoshi ^a   Ochiai, Hidenobu ^c   Shimoda, Kazuya ^d   Ishikawa, Fumihiko ^e   Ueda, Akira ^a   Kikuchi, Ikuo ^a  

^a MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF MIYAZAKI HOSPITAL   (Japan)

^d UNIVERSITY OF MIYAZAKI   (Japan)

^e Institute of Physical and Chemical Research   (Japan)

Author keywords

Adult T cell leukemia lymphoma; Early and high remission; Mogamulizumab; Refractory ATL; Relapse and progression; Survival

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR4 ANTAGONIST; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MOGAMULIZUMAB; PREDNISOLONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MALE; MIDDLE AGED; OINTMENT; OVERALL SURVIVAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN BIOPSY; T CELL LEUKEMIA; THROMBOCYTOPENIA; VERY ELDERLY; DISEASE COURSE; LEUKEMIA-LYMPHOMA, ADULT T-CELL; PATHOLOGY; RECURRENT DISEASE; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84971476169     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.55.6312     Document Type: Article

References (22)

1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50: 481-492, 1977.
2. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA 81: 2534-2537, 1984.
3. Tajima K, Kuroishi T. Estimation of rate of incidence of ATL among ATLV (HTLV-I) carriers in Kyushu, Japan. Jpn J Clin Oncol 15: 423-430, 1985.
4. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemialymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79: 428-437, 1991.
5. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSFsupported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113: 375-382, 2001.
6. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemialymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25: 5458-5464, 2007.
7. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol 27: 453-459, 2009.
8. Ishitsuka K, Tamura K. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol 80: 185-196, 2008.
9. Uozumi K. Treatment of adult T-cell leukemia. J Clin Exp Hematop 50: 9-25, 2010.
10. Tsukasaki K, Tobinai K. Clinical Trials and Treatment of ATL. Leuk Res Treatment 2012: 101754, 2012.
11. Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 19: 829-834, 2005.
12. Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 105: 4143-4145, 2005.
13. Tanosaki R, Uike N, Utsunomiya A, et al. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant 14: 702-708, 2008.
14. Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 116: 1369-1376, 2010.
15. Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood 120: 1734-1741, 2012.
16. Yamada Y, Atogami S, Hasegawa H, et al. Nationwide survey of adult T-cell leukemia/lymphoma (ATL) in Japan. Rinsho Ketsueki 52: 1765-1771, 2011.
17. Kawano N, Yoshida S, Kuriyama T, et al. Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult Tcell Leukemia-Lymphoma at a Single Institution over a 7-year Period (2006-2012). Intern med 54: 1489-1498, 2015.
18. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemialymphoma: a multicenter phase II study. J Clin Oncol 30: 837-842, 2012.
19. Taniguchi H, Imaizumi Y, Makiyama J, et al. Outcome of patients with relapsed/refractory adult T-cell leukemia-lymphoma after salvage therapy. Rinsho Ketsueki (Jpn J Clin Hematol) 54: 2159-2166, 2013 (in Japanese, Abstract in English).
20. Jo T, Ishida T, Takemoto S, et al. Randomoized phase II study of mogamulizumab (KW-0761) plus mLSG 15 versus mLSG 15 alone for newly diagnosed aggressive ATL. J Clin Oncol 31: 8506, 2013.
21. Ishida T, Ito A, Sato F, et al. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 104: 647-650, 2013.
22. Yonekura K, Kanzaki T, Gunshin K, et al. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemialymphoma: cutaneous adverse reactions may predict the prognosis. J Dermatol 41: 239-244, 2014.